Does Medicare Advantage Cover Ozempic?

How Medicare Advantage Handles Ozempic Coverage

Medicare Advantage (MA) plans, also called Medicare Part C, bundle hospital, medical, and usually prescription drug (Part D) benefits into a single plan offered by private insurers such as UnitedHealthcare, Humana, Aetna, and Blue Cross Blue Shield affiliates. Each carrier builds its own formulary, but all must follow federal CMS rules that define what Part D can and cannot pay for.

The CMS Coverage Rule for GLP-1 Drugs

Under 42 CFR §423.100, Part D plans are prohibited from covering drugs prescribed solely for weight loss or cosmetic purposes. This means Ozempic prescribed off-label for obesity alone will be denied regardless of which MA carrier you have. The only exception CMS has introduced applies to Wegovy (semaglutide 2.4 mg) after the FDA expanded its label in March 2024 to include reduction of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease and obesity [1]. Ozempic does not carry this MACE indication, so the exception does not apply to it.

When Coverage Is Approved

Coverage is approved when your prescriber documents a diagnosis of type 2 diabetes mellitus (ICD-10 code E11.x). Most plans also require a recent A1C value, typically 7.0% or above, though some plans set the threshold at 6.5% to match the American Diabetes Association diagnostic cutoff [2]. A fasting glucose or oral glucose tolerance test result may substitute for A1C in certain plan protocols.

Formulary Tier Placement Across Major Carriers

Where Ozempic sits on a formulary directly determines your monthly out-of-pocket cost. MA plans typically use a five- or six-tier structure.

Tier 3 vs. Tier 4: What the Difference Means for Your Copay

Tier 3 (preferred brand) copays generally range from $47 to $80 per 30-day supply. Tier 4 (non-preferred brand) copays climb to $90 to $150 or higher, and some plans charge coinsurance of 25% to 33% instead of a flat copay. In the catastrophic phase of Part D (after total out-of-pocket spending exceeds $8,000 in 2026), beneficiaries pay $0 for covered drugs under the Inflation Reduction Act provisions that eliminated catastrophic-phase cost-sharing [3].

Carrier-Specific Variations

UnitedHealthcare AARP MA plans often list Ozempic on Tier 4 with prior authorization. Humana Gold Plus and similar HMO plans tend to place it on Tier 3 with step therapy. Aetna Medicare Advantage PPO plans have varied by region, with some formularies listing Ozempic on Tier 3 and others on Tier 5 (specialty). The only reliable way to confirm tier placement is to search the plan's online formulary tool or call the number on the back of your member ID card. CMS requires every Part D plan to publish a searchable formulary at medicare.gov/plan-compare [4].

Prior Authorization: What Your Doctor Must Submit

Prior authorization (PA) is the gatekeeper for Ozempic on virtually every MA formulary. Your prescriber's office, not you, initiates the PA. The process involves submitting clinical documentation to the plan's pharmacy benefit manager.

Standard PA Criteria

Most plans require all of the following:

• Confirmed diagnosis of type 2 diabetes (chart notes plus lab values)
• A1C at or above 7.0% on current therapy (some plans accept 6.5%)
• Documented trial and failure of, or contraindication to, metformin (see step therapy below)
• Prescriber attestation that Ozempic is being used for glycemic control, not weight management

Plans typically respond within 72 hours for a standard request and 24 hours for an expedited (urgent) request. If the plan does not respond within those windows, the request is automatically deemed approved under CMS rules [5].

Common Reasons for PA Denial

The most frequent denial reasons include: missing A1C documentation, no evidence that metformin was tried first, or the prescriber listed an ICD-10 code for obesity (E66.x) rather than diabetes (E11.x) as the primary diagnosis. A 2022 analysis in the American Journal of Managed Care found that approximately 23% of GLP-1 receptor agonist PAs were initially denied, with documentation errors accounting for about half of those denials [6].

Step Therapy Requirements

Step therapy, sometimes called "fail first," means the plan requires your prescriber to show that you tried a less expensive medication before approving a costlier one.

Typical Step Therapy Sequence

For Ozempic, the most common step therapy sequence across MA plans is:

1. Metformin (first-line per ADA Standards of Care) [2]
2. A sulfonylurea or DPP-4 inhibitor (second-line in some plan protocols)
3. Ozempic or another GLP-1 RA (approved after documented inadequate response or intolerance)

"Inadequate response" usually means A1C remains above goal (7.0% or above) after at least 90 days on the prior agent at an adequate dose. "Intolerance" includes documented gastrointestinal side effects, lactic acidosis risk factors for metformin, or a contraindication such as eGFR below 30 mL/min/1.73 m².

Bypassing Step Therapy

Your prescriber can request a formulary exception if clinical evidence supports skipping a step. For example, SUSTAIN-7 (N=1,201) demonstrated that semaglutide 0.5 mg and 1.0 mg produced significantly greater A1C reductions (−1.5% and −1.8%, respectively) compared with dulaglutide 0.75 mg and 1.5 mg (−1.1% and −1.4%) over 40 weeks [7]. Citing this trial, along with the ADA's recommendation that GLP-1 RAs are preferred second-line agents in patients with established atherosclerotic cardiovascular disease or high cardiovascular risk, can strengthen an exception request [8].

What About Ozempic for Weight Loss on Medicare Advantage?

This is where most confusion and frustration occurs. The short answer: CMS prohibits Part D coverage of any drug prescribed solely for weight management.

The Regulatory Barrier

The Social Security Act §1860D-2(e)(2)(A) explicitly excludes drugs "used for anorexia, weight loss, or weight gain" from Part D coverage. Even though Ozempic's active ingredient (semaglutide) is the same molecule in Wegovy, the FDA approval labels differ. Ozempic's label is limited to type 2 diabetes [9]. A prescriber who submits a PA listing obesity as the primary indication will receive an automatic denial.

The Wegovy MACE Exception

Since March 2024, CMS has permitted Part D plans to cover Wegovy specifically for cardiovascular risk reduction in adults with BMI 27 or above and established cardiovascular disease, based on the SELECT trial (N=17,604) that showed a 20% relative risk reduction in MACE [10]. This exception does not extend to Ozempic. Patients who want semaglutide covered for weight-related cardiovascular benefit must have their prescriber write for Wegovy 2.4 mg and meet the SELECT trial population criteria.

Dual-Diagnosis Workaround

If a patient has both type 2 diabetes and obesity, the prescriber can legitimately prescribe Ozempic for diabetes. The weight loss that follows is a secondary benefit. This is clinically appropriate (the ADA recommends GLP-1 RAs for patients with T2D who also need weight management) and does not violate CMS rules, as long as the primary indication on the claim is diabetes [8].

How to Appeal a Medicare Advantage Denial of Ozempic

MA plans deny Ozempic coverage more often than many beneficiaries expect. A structured appeal can reverse the decision.

The Five Levels of Medicare Appeal

1. Plan redetermination (Level 1): Written request to the MA plan within 60 days of denial. The plan must decide within 7 days (72 hours if expedited). Include updated labs, prescriber letter of medical necessity, and relevant clinical guidelines.
2. Independent Review Entity reconsideration (Level 2): If Level 1 fails, the plan automatically forwards your case to MAXIMUS Federal Services, the CMS-contracted Independent Review Entity. MAXIMUS has 7 days to decide.
3. Office of Medicare Hearings and Appeals (Level 3): An Administrative Law Judge hearing, available if the amount in controversy exceeds $190 (2026 threshold).
4. Medicare Appeals Council (Level 4): Review of the ALJ decision.
5. Federal District Court (Level 5): Available if the amount exceeds $1,900 (2026 threshold).

Tips That Improve Appeal Success

According to CMS data, approximately 75% of MA Part D appeals that reach the external review level (Level 2) are decided in the beneficiary's favor [11]. The most effective appeal letters include:

• A prescriber statement explaining why Ozempic is medically necessary for this specific patient (not a generic form letter)
• A1C trend data showing inadequate control on prior agents
• A citation to ADA Standards of Care supporting GLP-1 RA use in the patient's clinical scenario
• Documentation of adverse effects from any medications the plan suggested as alternatives

Can You Use the Novo Nordisk Savings Card with Medicare?

No. Federal law (the Anti-Kickback Statute, 42 U.S.C. §1320a-7b) prohibits pharmaceutical manufacturer copay cards, discount programs, and coupons from being applied to any federally funded insurance, including Medicare Advantage, traditional Medicare, Medicaid, TRICARE, and VA benefits [12]. The Novo Nordisk Ozempic Savings Card is valid only for commercially insured patients and those paying cash.

Alternative Cost-Reduction Strategies

• State Pharmaceutical Assistance Programs (SPAPs): Some states (New York, Pennsylvania, New Jersey, and others) operate programs that supplement Part D coverage.
• Extra Help / Low-Income Subsidy (LIS): Beneficiaries with limited income and resources may qualify for the Medicare Part D LIS, which can reduce copays to $0 to $11 per prescription [4].
• Manufacturer Patient Assistance Programs: Novo Nordisk's PAP provides free Ozempic to qualifying uninsured or underinsured patients, but Medicare beneficiaries generally do not qualify unless they fall into the coverage gap and meet income thresholds.

Ozempic Dosing and What Medicare Approves

The FDA-approved dosing schedule for Ozempic in type 2 diabetes starts at 0.25 mg subcutaneously once weekly for 4 weeks (initiation dose, not for glycemic control), then increases to 0.5 mg once weekly [9]. After at least 4 weeks at 0.5 mg, the dose may increase to 1.0 mg weekly, and if additional glycemic control is needed, to 2.0 mg weekly.

What Plans Typically Authorize

Most MA plans authorize 0.5 mg and 1.0 mg pens without dose-specific restrictions once the PA is approved. The 2.0 mg dose sometimes triggers a secondary review because it was added to the label in 2022 and some formulary committees have not yet updated their protocols. If your plan denies the 2.0 mg pen, your prescriber can submit a formulary exception citing the SUSTAIN FORTE trial (N=961), which demonstrated that semaglutide 2.0 mg reduced A1C by 2.2% compared with 1.9% for the 1.0 mg dose over 40 weeks in patients with inadequately controlled T2D [13].

Quantity Limits

Part D plans commonly authorize one pen (four weekly doses) per 28-day fill. Requests for quantities exceeding this will require a quantity limit exception.

How Ozempic Compares to Covered Alternatives on Medicare Formularies

If Ozempic is denied or too expensive on your plan, several GLP-1 receptor agonists and other injectable options carry different formulary positions.

| Drug | Typical MA Tier | Once-Weekly? | A1C Reduction (key trial) | |---|---|---|---| | Ozempic (semaglutide) | 3 or 4 | Yes | −1.5% to −1.8% (SUSTAIN-7) [7] | | Trulicity (dulaglutide) | 3 | Yes | −1.1% to −1.4% (SUSTAIN-7) [7] | | Rybelsus (oral semaglutide) | 3 or 4 | Daily (oral) | −1.3% (PIONEER 1, N=703) [14] | | Mounjaro (tirzepatide) | 4 or 5 | Yes | −2.0% to −2.6% (SURPASS-2, N=1,879) [15] | | Victoza (liraglutide) | 3 | Daily | −1.2% (LEAD-6, N=1,091) |

Trulicity is the most commonly preferred GLP-1 RA on MA formularies because Eli Lilly has negotiated favorable rebates with many Part D plan sponsors. If your goal is semaglutide specifically, Rybelsus (oral semaglutide) may sit on a lower tier than Ozempic on some formularies.

Timeline: From Prescription to First Injection

Getting Ozempic through a Medicare Advantage plan typically follows this sequence:

1. Day 1: Prescriber submits electronic PA to the plan's PBM
2. Days 1 to 3: PBM reviews and responds (standard timeline)
3. Day 3 to 5: If approved, prescription is sent to pharmacy; if denied, prescriber receives denial reason
4. Days 5 to 10 (if denied): Prescriber submits Level 1 appeal with supporting documentation
5. Days 10 to 17: Plan issues redetermination decision
6. Days 17 to 24 (if still denied): Case goes to MAXIMUS for external review

Patients who need Ozempic urgently for severe hyperglycemia (A1C above 10% or symptomatic) should ask their prescriber to file an expedited PA, which compresses the timeline to 24 hours [5].